MiyakisSLockshinMDAtsumiet al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
ErkanDLockshinMD. Non-criteria manifestations of antiphospholipid syndrome. Lupus2010; 19: 424–427.
3.
YouinouPRenaudineauY. The antiphospholipid syndrome as a model for B-cell-induced autoimmune diseases. Thromb Res2004; 114: 363–369.
4.
KhattriSZandman-GoddardGPeevaE. B-cell directed therapies in antiphospholipid antibody syndrome: new directions based on murine and human data. Autoimmun Rev2012; 11: 717–722.
5.
KahnPRamanujamMBethunaickanRet al.Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum2008; 58: 2824–2834.
6.
ErreGLPardiniSFaeddaRet al.Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus2008; 17: 50–55.
7.
ErkanDVegaJRamoGet al.A Pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum2013; 65: 464–471.
8.
BermanHRodríguez-PintóICerveraRet al.Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev2013; 12: 1085–1090.
9.
KimSSKirouKAErkanD. Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis2012; 3: 11–23.
